Document is current

Article History

Accepted: 20 July 2023

First Online: 8 August 2023

Declarations

:

: This work was supported by the French Medicines Agency (Agence Nationale de Sécurité du Médicament et des Produits de Santé, ANSM) (Grant number 2019S015), in the context of a partnership with the Health Product Epidemiology Scientific Interest Group (EPI-PHARE). The present study is part of the Drugs Systematized Assessment in real-liFe EnviRonment (DRUGS-SAFE^<u>R</u>) research program. This program aims at providing an integrated system allowing the concomitant monitoring of drug use and safety in France. The potential impact of drugs, frailty of populations and seriousness of risks drive the research program. The French Medicines Agency played no role in the study design, conduct, and interpretation of results or discussion. This publication represents the views of the authors and does not necessarily represent the opinion of the French Medicines Agency.

: The authors declare they have no conflict of interest.

: By agreement of the French Data Protection Supervisory Authority, neither ethics committee approval nor informed consent were required for this observational study based on medico-administrative databases because of the anonymous nature of the data.

: Not applicable.

: Not applicable.

: No additional data available by author (French law to access SNDS ExternalRef removed). The SAS code used is available from the corresponding author, antoine.pariente@u-bordeaux.fr, upon request.

: Conception or design of the work: SMR, AJM, MT, BB, AP; data acquisition and analysis: AJM; data interpretation: SMR, AJM, MT, BB, AP; manuscript drafting: SMR, AJM, AP; manuscript critical reviewing: SMR, AJM, MT, BB, AP; final approval of the version to be published: SMR, AJM, MT, BB, AP; administrative, technical, or material support: SMR, AJM; study supervision: AP. All the authors have read and approved the final submitted manuscript, and agree to be accountable for the work.